03.07.23 -- 2023 Cell & Gene Therapy Outlook; Executives Speak from JPM Healthcare Conference and more -- Listen Now!

Check out the latest episodes from Cell & Gene: The Podcast and Business of Biotech listed below. As a member of the Life Science Connect community, you have access to content beyond our weekly newsletters, including our podcast series.

If you are responsible for manufacturing and outsourcing decisions at your company, check out our Cell & Gene Collaborative bi-weekly newsletter. Curated by director Anna Rose Welch, she singles out the most informative and entertaining manufacturing-centric headlines to keep you in the know.

Miguel Forte is entrepreneur in residence at AdBio, a VC firm based in France, and president elect of ISCT. Forte and Cell & Gene: The Podcast host Erin Harris break down market outlook perspective for the cell and gene therapy space. He provides valuable tips to employ when seeking VC partnership, and he covers ISCT's primary focus areas and what to expect from ISCT 2023 Paris.

Andy Ramelmeier, EVP head of technical operations at Sangamo Therapeutics, a biotech based in Brisbane, CA, explains the why behind the company's decision to build its own Phase 1/2 cGMP AAV in-house facility. He also talks broadly about manufacturing cell and gene therapies and the potential and realistic solutions needed to drive down manufacturing costs.

We caught up with Bolt Biotherapeutics CEO Randall Schatzman, Ph.D., and CMO Edith Perez, M.D., at the JP Morgan Healthcare Conference in San Francisco last month for a conversation on the IPO process, the impacts it's had on the go-forward plan at Bolt Bio, the company's clinical progress, and its collaboration strategy moving forward. 

Matt Coffey, Ph.D., earned his Ph.D. in 1998 and turned his doctoral thesis into a biopharma company called Oncolytics in 1999. Coffey shares on his abrupt transition from academia to industry, tells tales of the company's backstory, and updates us on its aggressive clinical activity spanning seven wide-ranging oncology programs.

This episode features a conversation with Sangamo Therapeutics CEO Sandy Macrae, Ph.D., who rationalizes the company's aggressive pipeline development and its decision to invest in multinational AAV and cell therapy manufacturing facilities in France and California.

Is it past time for a new approach to the COVID vaccine? Ocugen Chairman of the Board, Founder, & CEO Shankar Musunuri, Ph.D., says yes, and his ideals would mark significant improvements: fewer shots, better durability, less post-vaccination transmission, and safety proven by time-tested technology.